Pharmaceutical

US DoD enlists VitriVax to develop one-shot vaccine for melioidosis

B. pseudomallei is resistant to many antibiotics and, without treatment, can be lethal to those infected.

Jul 19, 2023 - 20:00
US DoD enlists VitriVax to develop one-shot vaccine for melioidosis
B. pseudomallei is resistant to many antibiotics and, without treatment, can be lethal to those infected.
Read the original article

Tags:

Previous Article

Amarin restructures to counter downturn following Vascepa generics

Next Article

Santhera and Catalyst to market DMD drug vamorolone in North America

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

US Elections: Vivek Ramaswamy makes brazen debate debut

US Elections: Vivek Ramaswamy makes brazen debate debut

Aug 24, 2023

Silence announces $120m private placement for depositary shares

Silence announces $120m private placement for depositar...

Feb 6, 2024

Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug

Merck KGaA abandons Phase III trial for $1.08bn head & ...

Jun 26, 2024